Tactic Pharma Llc Sells 33,334 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) major shareholder Tactic Pharma Llc sold 33,334 shares of the stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the sale, the insider now owns 822,255 shares in the company, valued at $28,778,925. The trade was a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Monopar Therapeutics Trading Down 13.3 %

Monopar Therapeutics stock opened at $30.00 on Friday. The company has a market capitalization of $183.39 million, a PE ratio of -15.23 and a beta of 1.01. The stock has a 50-day moving average price of $38.29 and a two-hundred day moving average price of $25.03. Monopar Therapeutics Inc. has a 12 month low of $1.72 and a 12 month high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Monday, March 31st. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($0.36) by ($1.87). As a group, analysts predict that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current fiscal year.

Institutional Trading of Monopar Therapeutics

Several institutional investors have recently modified their holdings of MNPR. JPMorgan Chase & Co. bought a new position in Monopar Therapeutics during the 4th quarter worth $45,000. Geode Capital Management LLC raised its position in shares of Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after acquiring an additional 24,530 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Monopar Therapeutics in the fourth quarter worth approximately $2,861,000. Point72 Asset Management L.P. bought a new stake in Monopar Therapeutics in the fourth quarter valued at approximately $3,694,000. Finally, RA Capital Management L.P. acquired a new stake in Monopar Therapeutics during the 4th quarter valued at approximately $11,247,000. Institutional investors own 1.83% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MNPR. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Monopar Therapeutics in a research report on Tuesday, April 1st. Piper Sandler reiterated an “overweight” rating and issued a $76.00 target price on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. Finally, Jones Trading reaffirmed a “hold” rating on shares of Monopar Therapeutics in a report on Wednesday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $44.00.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.